Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 5,277,335	$ 3,097,711
General and administrative	2,096,954	594,981
Change in fair value of convertible affiliated note		(684,436)
Operating loss	(7,374,289)	(3,008,256)
Other expense, net:
Interest expense, net	(848)	(743,695)
Other expense, net	(401,964)	(94,243)
Net loss	$ (7,777,101)	$ (3,846,194)
Per common share data:
Basic and diluted net loss per common share	$ (0.23)	$ (0.16)
Weighted average number of common shares outstanding	33,504,472	24,177,315
Other comprehensive income:
Foreign currency translation gain	$ 522,771	$ 353,305
Comprehensive loss	$ (7,254,330)	$ (3,492,889)